Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | LCAT | P04180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249340 | 0.87 | CYP11B1 (0.51) | CYP11B1CYP11B2OPRM1OPRL1CD274 | |
| SCHEMBL20249284 | 0.80 | BPTF (0.33) | — | |
| SCHEMBL18290988 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2OPRM1OPRL1CCNC | |
| SCHEMBL20255666 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2OPRM1OPRL1CCNC | |
| SCHEMBL20249295 | 0.76 | ALDH1A1 (0.40) | CYP11B1 | |
| SCHEMBL20249303 | 0.75 | ALDH1A1 (0.49) | — | |
| SCHEMBL20038231 | 0.73 | CHRNB2 (0.35) | — | |
| SCHEMBL20249311 | 0.72 | HRH4 (0.33) | — | |
| SCHEMBL20249270 | 0.72 | TRPV1 (0.30) | — | |
| SCHEMBL20037591 | 0.71 | GFER (0.40) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CYP11B1 963/4885CYP11B2 1006/4885OPRM1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.